This study was conducted to investigate the activity and toxicity of 5fluorouracll + folinic acid + mitomycin C combined with alpha 2b Interferon in advanced colorectal cancer based upon recent studies suggesting a possible biochemical modulation of 5 fluorouracil by interferon.
Patients and methods
Between June 1990 and April 1991 25 previously untreated patients with advanced colorectal carcinoma were treated with mitomycin C 10 mg/m2 iv bolus on day 1, 5fluorouracil 375 mg/m2 on days 1 to 4 and folinic acid 200 mg/m2 on days 1 to 4 every 4 weeks, combined with alpha 2b interferon 3 million U day continuously.
Response
Of the 25 patients entered into the study, 20 were evaluable for response as 5 patients withdrew due to toxicity (grade 3-4 thrombocytopenia in 4 cases and fatigue in 1). No complete response was recorded, 6 patients had partial remission (30 %; 95 % confidence interval, 10 % to 50 %), 4 experienced no change and 10 showed progressive disease. The toxicity of this regimen was significant, particularly myelosuppression.
Conclusions
This combination showed a significant toxicity and low response rate compared with other 5 fluorouracil based regimens in advanced colorectal cancer.
AaproM.S., AlbertD.S., SalomonS.E.: Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother. Pharmacol., 10: 161–166, 1983.
2.
AdjaniJ.A., RiosA.A., EndeK., AbbruzzeseJ.L., EdwardsC., FaintuchJ.S., SaksS., GuttermanJ.U., LevinB.: Phase I and II study of the combination of recombinant human interferon gamma and 5fluorouracil in patients with advanced colo-rectal cancer. J. Biol. Response Mod., 8: 140–146, 1989.
3.
Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896–903, 1992.
4.
CascinuS., FedeliA., Luzi FedeliS., CatalanoG.: Double biochemical modulation of 5fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. Ann. Oncol., 3: 489–491, 1992.
5.
CrookeS.T., BradnerW.T.: Mitomycin C: a review. Cancer Treat. Res., 3: 121–139, 1986.
6.
DuillardJ.Y., LeborgneJ., DanielouJ.Y., LehurP.A., PottronL., Le NeelJ.C., BolzerJ.L., JutelP.: Phase II trial of 5 fluorouracil (5FU) and recombinant alpha interferon (rIFN-alpha) (Intron A) in metastatic previously untreated colorectal cancer. Proc. Am. Soc. Clin. Oncol., 10: 139, 1991 (abstr. 422).
7.
EliasL., SandovalJ.M.: Interferon effects upon fluorouracil metabolism by HL60 cells. Biochem. Biophys. Res. Comm., 163: 867–874, 1990.
8.
FornasieroA., DanieleO., GhiottoC., AversaS.M., MorandiP., FiorentinoM.V.: Alpha 2 interferon and 5fluorouracil in advanced colorectal cancer. Tumori, 76: 385–388, 1990.
9.
GremJ.L., McAtesN., MurphyR.F., BalisF.M., SteinbergS.M., HamiltonJ.M., SorensenJ.M., SartorO., KramerB.S., GoldsteinL.J.: A pilot study of interferon alpha 2a in combination with fluorouracil plus high dose leucovorin in metastatic gastrointestinal carcinoma. J. Clin. Oncol., 9: 1811–1820, 1991.
10.
HubermanM., Mc ClayE., AtkinsM., GoldsweigH., BonannoD., LaytonM., TessitoreJ.: Phase II trial of 5-fluorouracil (5FU) and recombinant alpha 2a interferon (IFN) in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 10: 153, 1991 (abstr. 478).
11.
InoshitaG., YalavarthiP., MurthyS., BuddG.T., AndresenS., NetajiB., GibsonV., SergiJ., BukowskiR.M.: Phase I trial of leucovorin (LV) and rhIFN-alpha 2a in metastatic colorectal cancer (CR CA). Proc. Am. Soc. Clin. Oncol., 10: 152, 1991 (abstr. 475).
12.
JaiyesimiI., PazdurR., PattY.Z., AjaniJ., AbbruzzeseJ.R., DaughertyK., LevinB.: Phase II study of recombinant interferon alpha 2a (rIFN) and continuous 5fluorouracil (5FU) in metastatic colorectal carcinoma. Proc. Am. Soc. Clin. Oncol., 10: 147, 1991 (abstr. 455).
13.
JohnW.J., CantrellJ., SmithM., MunnR., NeefeJ.: Treatment of advanced colorectal cancer with low dose continuous infusion fluorouracil and interferon alpha. Proc. Am. Soc. Clin. Oncol., 10: 148, 1991 (abstr. 457).
14.
KemenyN.: Role of chemotherapy in the treatment of colorectal carcinoma. Semin. Surg. Oncol., 3: 190–214, 1987.
KreuserE.D., MatthiasM., BoewerC., Boese-LandgrafJ., SchalhornA., HilgenfeldR.U., ThielE.: Double modulation of 5 fluorouracil with interferon alpha 2b and folic acid in metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 10: 150, 1991 (abstr. 468).
17.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment. Cancer, 47: 207–214, 1981.
18.
PazdurR., MooreD.F.Jr., BradyB.: Modulation of fluorouracil with recombinant alfa interferon: MD Anderson clinical trial. Semin. Oncol., 19: 176–179, 1992 (suppl. 3).
19.
PiedboisP., JimonetJ.F., FeuilhadeF., Le PechouxC., LevyC., BrunB., RotmanN., DelchierJ.C., BlasquetsM., ThillL.: 5FU, folinic acid and alpha 2a interferon combination in advanced gastrointestinal cancer. Proc. Am. Soc. Clin. Oncol., 10: 141, 1991 (abstr. 430).
20.
PuntC.J., De MulderP.H., BurghoutsJ.T., WagenerD.J.: A phase I-II study of high dose 5 fluorouracil (5FU), leucovorin (LV) and alpha interferon (alpha IFN) in patients with advanced colorectal cancer. Proc. Am. Soc. Oncol., 10: 150, 1991 (abstr. 465).
21.
QuesadaJ.R., TalpazM., RiosA., KurzrockR., GuttermanJ.U.: Clinical toxicity of interferon in cancer patients. A review. J. Clin. Oncol., 4: 234–243, 1986.
22.
RozencweigM., BleibergH., KenisY.: Mitomycin C therapy in advanced colorectal cancer. In: Mitomycin C: Current Impact on Cancer Chemotherapy.OgawaM., RozencweigM., StaquetM.J. (Eds.), pp. 76–88. Excerpta Medica, Amsterdam, 1982.
23.
SchmollH.J., Köhne-WömpnerC.H., HiddemannW., KnippH., WilkeH., BodensteinH., SchoffskiP., BokemeyerC., LohrmannH.P., PreissJ.: Interferon alpha 2b, 5fluorouracil and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I-II trial. Semin. Oncol., 19: 191–196, 1992 (suppl. 3).
24.
SchüllerJ., CzejkaM.J., SchernthanerG., FoglU., JagerW., MickscheM.: Influence of interferon alfa 2b with or without folinic acid on pharmacokinetics of fluorouracil. Semin. Oncol., 19: 93–97, 1992 (suppl. 3).
WadlerS., SchwartzE.L.: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res., 50: 3473–3486, 1990.
27.
WadlerS., WerstoR., WeinbergW., ThomsonD., SchwartzE.L.: Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res., 50: 5735–5739, 1990.
28.
WadlerS., SchwartzE.L., GoldmanM., LyverA., RaderM., ZimmermanM., ItriL., WeinbergV., WiernikP.H.: Fluorouracil and recombinant alpha 2a interferon: an active regimen against advanced colorectal carcinoma. J. Clin. Oncol., 7: 1769–1775, 1989.
29.
WadlerS., WiernikP.H.: Clinical update on the role of fluorouracil and recombinant interferon alpha 2a in the treatment of advanced colorectal carcinoma. Semin. Oncol., 17: 16–21, 1990 (suppl. 1).
30.
WehH.J., PlatzD., BraumannD., BuggischP., SchmiegelW.H., DrescherS., KlebergU.R., MullerleileU., Crone-MunzebrockW., HoffmanR.: Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant interferon alfa 2b: preliminary data of a phase II study. Semin. Oncol., 19: 180–184, 1992 (suppl. 3).
31.
WrigleyP.F., SlevinM.L., ClarkP., NiederleN., LundellG., CedermarkB., FalleniusA., BlomgrenH., OhlgrenH., SilferswaerdC., TheveN.O., VaughanR., BonnernE.M.: Alpha 2 interferon in combination with 5 fluorouracil for advanced colorectal carcinoma. Proc. Am. Soc. Clin. Oncol., 3: 146, 1984 (abstr. C-569).
